ClinicalTrials.Veeva

Menu

Interest of Thromboelastography (ROTEM) as a Biomarker of Revascularisation in Stroke (ROTEMPredict)

C

Caen University Hospital

Status

Unknown

Conditions

Stroke

Treatments

Biological: Thromboelastography

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

Revascularisation using recombinant tPA is the reference treatment of stroke. However, the efficacy of fibrinolysis is about 50%. Several factors, including the size of thrombus, have been associated with revascularisation efficacy.

The aim of this prospective study is to evaluate ex vivo the effect of tPA in patients with stroke with thromboelastography and to correlate results with the clinical outcome of patients. Results may predict revascularisation in patients with stroke.

Enrollment

64 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient (> 18 years) with a neurological deficit compatible with a neurovascular pathology eligible for fibrinolysis rtPA and having a proximal occlusion of the middle cerebral artery (segment M1 / M2) or basilar trunk objectified brain imaging (MRI angiography or angio CT).

Exclusion criteria

  • Any patient with major comorbidity, a pathology of hemostasis or anticoagulant treatment (vitamin K antagonist (VKA), direct oral anticoagulant).

Trial design

64 participants in 1 patient group

Success of revascularisation
Treatment:
Biological: Thromboelastography

Trial contacts and locations

1

Loading...

Central trial contact

Yohann REPESSE, MD PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems